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Assessment and treatment of Down
syndrome-associated arthritis: a survey of
pediatric rheumatologists
Anna Nicek1, Nasreen Talib1, Daniel Lovell2, Chelsey Smith3, Mara L. Becker4 and Jordan T. Jones3,5*

Abstract
Background: Inflammatory arthritis in children with Down syndrome (DS) was first described in 1984 and is now
termed Down syndrome-associated arthritis (DA). Studies have shown that DA is under-recognized with a 19month average delay in diagnosis. Additionally, most patients present with polyarticular, rheumatoid factor (RF) and
anti-nuclear antibody (ANA) negative disease. Current therapies for juvenile idiopathic arthritis (JIA) have been used,
but appear to be poorly tolerated, more toxic and less effective in patients with DA. There is currently no
standardized approach to the assessment or management of DA. The objective of this study was to describe
provider perspectives toward diagnostic and treatment approach of DA, to provide baseline information upon
which to design future studies.
Methods: An electronic survey, organized into sections regarding individual practices of assessment and treatment
approach of DA, was sent to the Pediatric Rheumatology electronic list-serv. Survey responses were voluntary and
results were analyzed by descriptive statistics.
Results: Of 90 survey responses received, 89 were included in the analysis (one was a duplicate response). The
respondents were mostly pediatric rheumatologist (94%), with greater than 10 years of experience (55%). The
majority (64%) currently see 1–3 patients with DA. Most view DA as the same disease as JIA (73%), and the majority
(63%) use a combination of history, exam and imaging to diagnose DA. The most ordered diagnostic tests are CBC
(97%) and ESR (96%). The most used treatments include NSAIDs (94%) and methotrexate (91%) followed by antiTNF agents (90%). Methotrexate is most administered by subcutaneous route (84%) at a dose of 15 mg/m2 (56%).
Oral corticosteroids were only used in 19% of the patients with DA.
Conclusion: This is the first study to evaluate provider perspectives towards the diagnostic and treatment approach
of DA. Most pediatric rheumatologists feel that DA and JIA are synonymous, and similar approaches to diagnosis
are employed, utilizing history, physical exam, laboratory tests, and imaging modalities. DA is treated similarly to JIA
with initiation of NSAIDs, disease-modifying anti-rheumatic drugs and biologic therapy. More research is needed to
determine optimal screening and therapeutic approach specific to DA.
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Background
Down syndrome (DS) is one of the most common birth
defects in the United States with approximately 5300
births annually resulting in an estimated birth prevalence
of 12.6 per 10,000 live births [1]. DS is a chromosomal disorder characterized by an extensive and heterogeneous
phenotype that results from a dosage imbalance of genes
located on human chromosome 21 [2]. This results in an
increased incidence of oncologic, autoinflammatory and
autoimmune conditions that lead to increased morbidity
and mortality in those individuals with DS. The comorbidities mentioned include but are not limited to leukemia,
celiac disease, thyroid disease, type I diabetes mellitus, and
arthritis [3, 4]. Inflammatory arthritis was first described
in children with DS in a small case series from 1984 [5].
More recently, children with DS and arthritis have been
termed Down syndrome-associated arthritis (DA), and the
estimated prevalence of DA has been reported to be 8.7
per 1000 children with Down syndrome [6].
At this time, DA remains under-diagnosed and largely
under-reported with an average delay of 19 months from
symptom onset to diagnosis [7]. By comparison, the
mean time from symptom onset to diagnosis for juvenile
idiopathic arthritis (JIA) is 3 months [8, 9]. Adding to
the challenges in diagnosis, many patients with DS also
present with noninflammatory musculoskeletal abnormalities (i.e. hypotonia, atlantoaxial instability, ligamentous laxity, and pes planus) that can lead to functional
limitation [10]. At the time of presentation, most patients with DA have polyarticular disease (five or more
joints with active arthritis) that is erosive, and primarily
affects the small joints of the hands and wrists [7, 8].
Many patients with DA present to the rheumatology
clinic thus therapies utilized to treat JIA often are used
to treat DA. The current treatment for JIA is broad and
based on many factors, but includes: nonsteroidal antiinflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologic therapies, and glucocorticoids [11]. Most children diagnosed with DA are
initially started on NSAID monotherapy and many require a second-line therapy with DMARDs. Of these, the
most frequently used is methotrexate despite its risk for
toxicity and intolerance [6, 7, 9]. Therapies for JIA have
been employed to treat DA with mixed results due to effectiveness and toxicity [7, 12]. Gaps in knowledge related to the optimal therapy and treatment approaches
to DA exist currently, and to date, there are no randomized controlled trials or standardized recommendations
for the treatment of DA. Many therapeutic agents with
different mechanisms of action have been used, but no
consistent approach to treatment has been outlined. The
aim of this study is to describe the current practices of
pediatric rheumatologists, including diagnostic and
treatment approaches of DA.
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Methods
Using the REDCap platform, an electronic survey was
created which consisted of 12 questions organized into
sections regarding responder demographic characteristics, assessment and evaluation, and treatment approach
of inflammatory arthritis in Down syndrome. Survey
questions used branching logic and asked if providers
were aware of DA, how many patients they cared for
with DA and how they diagnosed it. Additional questions asked about therapy and sequence of therapies
used to treat DA. The survey questions gave multiple
choices and, “choose all that apply” questions with a list
of laboratory tests, imaging studies, and therapy options.
Many questions had an “other” category for the respondent to fill-in responses that may not be listed.
Physicians, including fellows-in-training and nurse
practitioners specializing in pediatric, adult, and combined pediatric and adult rheumatology were invited by
e-mail to complete the survey. Participants were asked
to respond according to their personal experience, not
that of institution or group practices or based on medical literature. Respondents were asked to quantify their
experience by years of practice and number of cases
seen. The survey was electronically sent to the international pediatric rheumatology electronic list-serv (administered by McMaster University, Ontario). All
respondents voluntarily completed the survey.
The results were analyzed by descriptive statistics performed using IBM SPSS Statistics version 24.
Results
Of 90 survey responses, 89 were included in the analyses
as one was a duplicate response. The majority (94%) of
respondents were pediatric rheumatologists and the remainder were combined adult and pediatric rheumatology providers. Physicians were the respondents in 88
surveys (4 of these were fellow-in training) and one was
a nurse practitioner. Over half (55%) had 10+ years of
practice experience in the field of rheumatology. Nearly
half of the respondents (47%) had greater than 75% time
committed to clinical duties, and most practiced in an
urban location (94%) and in an academic setting (92%).
Many (64%) of those that responded have 1–3 patients
with DA that they care for, and 19% have never managed DA in their career. (Table 1).
Of the respondents, 73% view the arthritis seen in patients with DS as synonymous with JIA, while 11%
viewed it as a separate entity and 16% were unsure. The
majority (63%) of respondents diagnosed DA based on a
combination of history, exam, and imaging. The most
common imaging modalities used were X-ray (55%) and
ultrasound (49%). Magnetic resonance imaging (MRI)
and computerized tomography (CT) scans were used
less frequently at a rate of 27 and 1%, respectively. Most

Nicek et al. Pediatric Rheumatology

(2020) 18:57

Page 3 of 7

Table 1 Respondent characteristics
Characteristics

n (%)

Practice Scope
Pediatric Rheumatology

84 (94)

Adult Rheumatology

0 (0)

Combined Adult/Pediatric Rheumatology

5 (6)

Clinic Location
Urban

84 (94)

Rural

5 (6)

Clinic Setting
Academic

82 (92)

Private practice

7 (8)

Experience (by years of practice)
0–5 years

24 (27)

5–9 years

16 (18)

10+ years

49 (55)
a

Experience (by # of DA cases)
0

17 (19)

1–3

57 (64)

4–6

10 (11)

7–10

2 (2)

> 10

3 (4)

Clinical Time
0–25%

12 (14)

26–50%

10 (11)

51–75%

25 (28)

> 75%

42 (47)

a

Down syndrome-associated arthritis

respondents (93%) obtain laboratory tests at diagnosis
with complete blood count (CBC) (97%) and erythrocyte
sedimentation rate (ESR) (96%) being the most ordered
tests. Rheumatoid factor (RF) was the most common
arthritis-related laboratory test obtained (82%), followed
by human leukocyte antigen B-27 (HLA-B27) (60%).
Other laboratory tests including anti-nuclear antigen
(ANA), immunoglobulin G (IgG), complement, uric acid,
and lactic acid dehydrogenase (LDH) were obtained less
frequently (all less than 50%).
Regarding therapeutic treatment approaches, 74% used
NSAIDs as first line-treatment. The survey then asked
for subsequent treatment choices after therapeutic failure. For those that failed first-line therapy, methotrexate
was most often used as second-line treatment at 56%.
TNF-inhibitors were most frequently used as a third-line
agent at 64%. Anti-CTLA4 agents were most frequently
used as fourth line therapy, and anti-IL-6 inhibitors were
the most common fifth-line therapy in treatment when
others had failed. IASI (intra-articular steroid injections)
were used in small percentages during all treatment

attempts, but oral steroids were used in small percentages during the first and second attempts only (Fig. 1).
Methotrexate was more commonly given via subcutaneous route compared to the oral formulation and was
more commonly dosed at 15 mg/m2 once weekly compared to < 15 mg/m2 once weekly. The survey specifically asked about which therapies providers avoid in
children with DA and asked that respondents provide an
explanation as to why they were avoided. Oral steroids
were avoided most frequently (19%) and comments provided by participants indicate that steroids were mostly
avoided due to the adverse effects such as weight gain, risk
for gastrointestinal bleed, risk for infection, mood changes,
and exacerbation of comorbid conditions such as insulin
dependent diabetes mellitus. Leflunomide was avoided in
17% and methotrexate was avoided in 7% due to concern
for intolerance, cytopenias and liver toxicity associated
with both medications. Leflunomide was specifically
avoided due to the lack of an oral suspension and the long
half-life of the drug. Respondents also avoided Plaquenil
(15%) and sulfasalazine (14%) with most comments indicating concern for adverse effects and lack of efficacy of
those therapies in treating arthritis. There were 5% that
avoided anti-TNF agents, mostly due to concern for increased risk of malignancy, and 3% that avoided anti-IL-6
inhibitors due to concern for cytopenias.

Discussion
Down syndrome-associated arthritis (DA) remains a significant source of morbidity for children with Down syndrome (DS) [6]. Previous studies have shown that DA is
under-recognized with delays in diagnosis, frequently presents with extensive joint involvement, and optimal treatment approach and escalation remains unclear [6–8]. This
survey describes the real-world approach to diagnosis and
treatment of DA by surveyed pediatric rheumatologists.
Although most respondents felt that arthritis in a patient with DS is the same as JIA, we would argue that
these may in fact be different diseases despite a similar
phenotypic presentation. As JIA is idiopathic in nature,
for it to occur in a child with DS may contradict that
idea, as the arthritis may be due to downstream metabolic and immunologic effects from the genetic abnormality of DS. In a cross-sectional survey of parents to
children with DS in New York a prevalence of arthritis
was reported to be 0.2% [13], which would indicate arthritis is uncommon in DS. Additionally, 19% of respondents to this survey have never managed a case of DA,
however, newer studies suggest the incidence and prevalence of DA are nearly 2–3 times greater than previously
thought [7, 8, 14]. This is thought to be due to lack of
awareness of arthritis in DS and features of DS including
joint hypermobility, intellectual disability, and poor language skills that may make diagnosis more difficult [8].
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Fig. 1 Treatment approach and percentage of use among all respondents. NSAIDs nonsteroidal anti-inflammatory drugs, IASI intra-articular
steroid injection, MTX methotrexate, sulfa sulfasalazine, HCQ hydroxychloroquine, Lef leflunomide, Anti-TNF Inhibitor (etanercept, adalimumab,
infliximab, golimumab, etc.), Anti-CTL4 (abatacept), Anti-IL-1 (anakinra, canakinumab), Anti-IL-6 (tocilizumab)

More recent studies are beginning to find distinct differences between DA and JIA such as lack of elevated inflammatory markers and ANA positivity in DA
compared with JIA [7, 8]. Additionally, more reports
suggest that trisomy 21 promotes pro-inflammatory cytokines and T cell dysregulation that results in chronic
autoinflammation and immune dysregulation that could
be the driver of DA and other autoinflammatory diseases
seen in children with DS [15–17].
As the rheumatologic and immunologic community is
becoming more aware of these findings, more focused
efforts have been put forth to explore differences between the two diseases. A recent study in children with
DA did show immunologic differences between DA and
JIA, with those with DA having increased polyreactive
T-helper cells, more elevation of serum inflammatory
cytokines and reduced T-regulatory cells, as well as a
marked increase in synovial inflammation compared to
JIA [16]. While this may indicate a different pathogenesis for DA compared with JIA, more evidence is needed
to clearly elucidate and fully explore the differences.
Additionally, previous reports indicate subtle clinical differences between DA and JIA such as the primary presentation and response to therapy, which may be
attributed to the heterogeneous nature of JIA or rather a
different pathogenesis in DA entirely. Further sophisticated immunologic studies are needed to determine differences, if any, between JIA and DA. Additionally, a

relative lack of exposure to or experience treating DA
may explain the reason most pediatric rheumatologists
feel that JIA and DA are the same disease, as many of
the rheumatologists surveyed had only managed 1–3
cases of DA and nearly 20% had never managed DA at
all. Part of the discrepancy observed in these responses
may be owed to practice type (size, academic affiliation),
location (city, region), and years of practice. However,
the correlation between these factors and the clinical experience with DA was not assessed in this survey as our
focus was mainly to identify diagnosis and management approaches of DA among pediatric rheumatology providers.
Furthermore, there is likely a lack of awareness of
DA among not only rheumatologists, but also the
general public and primary care providers. In the
most recent version of the American Academy of
Pediatrics Health Supervision of Children with Down
Syndrome [18] used by physicians to help guide
screening in patients with DS there is no mention of
surveillance for arthritis. Not addressed in our study
was the reason for referral to rheumatologists surveyed. This would be interesting to further investigate
where children were initially evaluated for symptoms
and what prompted referral to a rheumatologist. Assessment for screening and diagnostic criteria among
primary care physicians would be helpful in recognizing potential areas for education regarding arthritis in
the DS population.
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The diagnosis of JIA is a clinical diagnosis based on
the Edmonton 2001 International League of Associations
for Rheumatology (ILAR) criteria [19], however, there is
no clear guidance or criteria for the diagnosis of DA.
We found that clinicians surveyed use a similar diagnostic
approach to evaluate for DA as they would JIA by ordering more commonly used tests such as CBC, CRP, ESR
and RF, which could be explained if both diseases are considered synonymous. However, this approach may be
problematic, as studies have shown that up to 81% of children with DA present with polyarticular-RF-negative arthritis, a proportion significantly greater compared to 19%
of children with JIA [8, 20]. As well, studies have found
that CRP and ESR are elevated significantly less frequently
in DA compared to JIA [7, 8]. Respondents similarly use
radiologic modalities to help guide diagnosis of DA. X-ray
was most frequently used, likely as it is readily accessible,
reproducible, and relatively inexpensive. Unfortunately, Xray imaging, despite its relative ease is not sensitive
enough to reveal subtle or early arthritis, thus when bony
changes are present on X-ray, it may indicate long term
involvement and irreversible joint damage. Ultrasound
was the second most used imaging modality as it has similar accessibility, is easily tolerated, and has the added
benefit of avoiding radiation exposure as compared to Xrays. A limitation is that it is highly operator dependent
and may not be as reproducible from one technician to
another, making it more difficult to follow disease involvement over time [21]. Another limitation is the lack of validated standards for assessing the implications of
ultrasound findings in JIA and a complete lack of ultrasound studies in DA [21]. Fewer respondents reported
MRI use, which is likely related to the high cost, limited
availability, and risk of complications for children with DS
requiring sedation [8]. Previous studies have shown that
up to 80% of children with DA will present with erosive
disease and extensive joint changes noted on X-ray at
presentation [7]. Our study showed that providers are frequently using imaging modalities to help diagnosis, and
we feel it would be reasonable to encourage the use of imaging early in the diagnostic workup if suspicion for DA is
high. The idea of using ultrasound as part of a novel
screening tool to potentially diagnose DA sooner and help
follow disease is an intriguing idea but would need thorough validation in this population of patients.
Our study found that rheumatologists use treatment
strategies for DA that include initiation of NSAIDs, localized steroid injections, DMARDs, and biologics.
NSAIDs and intra-articular steroid injections (IASI)
were used most often as first line treatment of DA,
which is likely due to their relatively low side effect profile. IASI can be quickly performed in the office if the
child is easily distractible and compliant, however, the
child may require sedation for the procedure, and

Page 5 of 7

appropriate measures should be taken to ensure safe
sedation for a child with DS [22]. Beyond first line treatment with NSAIDs and IASI, most initiated methotrexate
at the JIA maximally effective recommended dose of 15
mg/m2 body surface area once weekly despite the known
increase in toxicity of methotrexate in children with DS
[23]. Biologic therapies, most often anti-TNF and CTLA4
agents, were used as third and fourth line treatments following the JIA guideline recommendation to initiate biologic therapies for more severe, DMARD-resistant and/or
polyarticular disease [11]. Oral corticosteroids were the
treatment that respondents most frequently listed as being
avoided. This appears to be due to the side effect profile,
issues related to weight gain, obesity, adverse effects, and
comorbid issues associated with DS [24].
Common adverse effects of methotrexate include
gastrointestinal toxicities (mucositis), liver toxicity, and
myelosuppression [25]. It is known that children with
DS getting treatment with high dose methotrexate for
leukemia as well as those getting low dose methotrexate
for the treatment of arthritis often require frequent lab
monitoring and dose adjustment as a result of those side
effects [7]. This is thought in part, to be due to gene
dosage effects for the multiple folate pathway enzymes
encoded on chromosome 21 [12]. For example, increased intracellular transport of methotrexate via
SLC19A1 and higher cellular methotrexate polyglutamates have been documented in hyperdiploid acute
lymphoblastic leukemia cells with extra copies of
chromosome 21 [26]. Nonetheless, our results show that
many providers still use methotrexate. This may be due
to the efficacy of the medication to treat arthritis, despite
the potential for adverse effects and toxicity. However,
there is also a lack of evidence to suggest the best
method to treat DA and the best strategy to escalate
therapy. There have been no studies to date that have
evaluated the best treatment practices for children with
DA, and since this was a study of rheumatologists, this
likely explains why most providers have followed therapy
guidelines for JIA. Further studies are needed to identify
safe and efficacious therapies for DA as well as ideal escalation of therapy.
Our study has several limitations including the low number of respondents, however, most respondents felt JIA and
DA were the same disease, and additionally this was
reflected in the assessment and treatment responses, which
would likely result in similar findings even with a larger
number of respondents. Participation bias was another limitation to our study as it is possible that many chose not to
complete the survey due to lack of experience with DA,
however, an increase in respondents with only a few or no
cases seen may not significantly alter the results. Another
limitation is that respondents may have answered the survey questions based on information other than their
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personal experience due to the hypothetical nature of the
questions and lack of details that would be present in a
case-based survey. However, the focus of this survey was
intended to describe current assessment and treatment approach to develop a baseline for evaluation and therapy.

Conclusion
This is the first study to evaluate the current practices of
diagnostic and treatment approaches of DA. Our study
found that most pediatric rheumatologists feel that DA
and JIA are synonymous and thus a similar approach to
diagnosis is employed, utilizing history, physical exam,
laboratory tests, and imaging. We also found that the
treatment approach to DA is like JIA, which is likely due
to lack of treatment guidelines for patients with DA.
More studies are needed to determine optimal screening
and therapeutic approaches for patients with DA.
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